NICER: A safer alternative to CRISPR/Cas9 for gene editing

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

No­var­tis an­nounced Wednes­day that Leqvio low­ered bad cho­les­terol lev­els, com­pared with a place­bo or the cho­les­terol-low­er­ing drug eze­tim­ibe, in pa­tients at low-to-mod­er­ate risk of de­vel­op­ing